Advertisement

State of the Art in Dendritic Cell Vaccination

  • J. de Vries
  • G. J. Adema
  • C. J. A. Punt
  • C. G. Figdor
Conference paper
Part of the Developments in Hematology and Immunology book series (DIHI, volume 38)

Abstract

Dendritic cells (DC) constitute a family of antigen-presenting cells defined by their morphology and their unique capacity to initiate a primary immune response [1]. It has been shown that DC pulsed with MHC class I peptides are potent inducers of a cytotoxic T lymphocyte (CTL) response in vitro [2]. Furthermore, the presence of DC in tumor tissue has been correlated with a favorable clinical prognosis. Therefore DC are thought to play a pivotal role in the induction of T cell-mediated anti-tumor responses in vivo [3–5]. We, and several other laboratories in the world have initiated clinical studies in which DC vaccines are used to treat cancer.

Keywords

Dendritic Cell Melanoma Patient Delay Type Hypersensitivity Keyhole Limpet Hemocyanin Immature Dendritic Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bakker, A.B, Schreurs, MW, Tafazzul, G et al. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2. 1-restricted anti-melanoma CTL line. Int J Cancer 1995;62:97–102.PubMedCrossRefGoogle Scholar
  2. 2.
    Celis, E, Tsai, V, Crimi, C, et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 1994;91:2105–09.PubMedCrossRefGoogle Scholar
  3. 3.
    Banchereau, J and Steinman, R M. Dendritic cells and the control of immunity. Nature 1998;392:245–52.PubMedCrossRefGoogle Scholar
  4. 4.
    Hart, DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997;90:3245–87.PubMedGoogle Scholar
  5. 5.
    Lanzavecchia, A. and Sallusto, F. Regulation of T cell immunity by dendritic cells. Cell 2001;106:263–66.PubMedCrossRefGoogle Scholar
  6. 6.
    De Vries, IJ, Eggert, AA, Scharenborg, NM, et al. Phenotypical and functional characterization of clinical grade dendritic cells. J Immunother 2002; 25:429–38.PubMedCrossRefGoogle Scholar
  7. 7.
    Romani, N, Gruner, S, Brang, D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83–93.PubMedCrossRefGoogle Scholar
  8. 8.
    Van den Eynde, BJ and van der Bruggen, P. T cell defined tumor antigens. Curr Opin Immunol 1997;9:684–93.PubMedCrossRefGoogle Scholar
  9. 9.
    Hsu, FJ, Benike, C, Fagnoni, F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2: 52–58.PubMedCrossRefGoogle Scholar
  10. 10.
    Nestle, FO, Alijagic, S, Gilliet, M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328–32.PubMedCrossRefGoogle Scholar
  11. 11.
    Thurner, B, Haendle, I, Roder, C, et al. Vaccination with mage-3A1 peptidepulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669–78.PubMedCrossRefGoogle Scholar
  12. 12.
    Nestle, FO., Banchereau, J, Hart, D. Dendritic cells: On the move from bench to bedside. Nat Med 2001;7:761–65.PubMedCrossRefGoogle Scholar
  13. 13.
    Brichard, V, Van Pel, A, Wolfel, T et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489–95.PubMedCrossRefGoogle Scholar
  14. 14.
    Parlato, S, Santini, SM, Lapenta, C et al. Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood 2001;98:3022–29.PubMedCrossRefGoogle Scholar
  15. 15.
    Takayama, T, Morelli, AE, Onai, N, et al. Mammalian and viral IL-10 enhance C-C chemokine receptor 5 but down-regulate C-C chemokine receptor 7 expression by myeloid dendritic cells: impact on chemotactic responses and in vivo homing ability. J. Immunol. 2001;166:7136–43.PubMedGoogle Scholar
  16. 16.
    De Vries, IJM, Krooshoop, DJEB, Scharenborg, NM, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003 (in press).Google Scholar
  17. 17.
    Kukutsch, NA, Rossner, S, Austyn, JM, Schuler, G, Lutz, MB. Formation and kinetics of MHC class I-ovalbumin peptide complexes on immature and mature murine dendritic cells. J. Invest. Dermatol. 2000;115:449–53.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2003

Authors and Affiliations

  • J. de Vries
    • 1
  • G. J. Adema
    • 1
  • C. J. A. Punt
    • 1
  • C. G. Figdor
    • 1
  1. 1.Dept. of Tumor Immunology and MedicineUniversity Medical Center NijmegenNijmegenThe Netherlands

Personalised recommendations